Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: A functional magnetic resonance imaging study

Journal of Clinical Psychiatry

Volumn 73, Issue 4, 2012, Pages 451-459

  Ruhé, Henricus G ^a   Booij, Jan ^a   Veltman, Dick J ^a   Michel, Martin C ^a   Schene, Aart H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PLACEBO;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG RESPONSE; FACIAL EXPRESSION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LIMBIC CORTEX; MAJOR DEPRESSION; MALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84860589325     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06584     Document Type: Article

References (52)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed. 03042 PubMed
2. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull. 2003;65(1):193-207. doi:10.1093/bmb/65.1.193 PubMed (Pubitemid 36406467)
3. Phillips ML, Drevets WC, Rauch SL, et al. Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatry. 2003;54(5):515-528. doi:10.1016/S06-323(03)0171-9 PubMed (Pubitemid 37289438)
4. Abler B, Erk S, Herwig U, et al. Anticipation of aversive stimuli activates extended amygdala in unipolar depression. J Psychiatr Res. 2007;41(6):511-522. doi:10.1016/j.jpsychires.206.07.020 PubMed (Pubitemid 46242139)
5. Anand A, Li Y, Wang Y, et al. Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry. 2005;57(10):1079-1088. doi:10.1016/j.biopsych.205.02.021 PubMed (Pubitemid 40615768)
6. Fu CH, Williams SC, Cleare AJ, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry. 2004;61(9):877-889. doi:10.101/archpsyc.61.9.87 PubMed (Pubitemid 39181077)
7. Surguladze S, Brammer MJ, Keedwell P, et al. A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder. Biol Psychiatry. 2005;57(3):201-209. doi:10.1016/j.biopsych.204.10.028 PubMed (Pubitemid 40187363)
8. Fitzgerald PB, Laird AR, Maller J, et al. A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp. 2008;29(6):683-695. doi:10.102/hbm.20426 PubMed (Pubitemid 351794123)
9. LeDoux J. The amygdala. Curr Biol. 2007;17(20):R868-R874. doi:10.1016/j.cub.207.08.05 PubMed (Pubitemid 47576655)
10. Sheline YI, Barch DM, Donnelly JM, et al. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry. 2001;50(9):651-658. doi:10.1016/S06-323(01)01263-X PubMed (Pubitemid 33043767)
11. Davidson RJ, Irwin W, Anderle MJ, et al. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry. 2003;160(1):64-75. doi:10.176/api.ajp.160.1.64 PubMed (Pubitemid 36042428)
12. Robertson B, Wang L, Diaz MT, et al. Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. J Clin Psychiatry. 2007;68(2): 261-267. doi:10.408/JCP.v68n0212 PubMed (Pubitemid 46362648)
13. Schaefer HS, Putnam KM, Benca RM, et al. Event-related functional magnetic resonance imaging measures of neural activity to positive social stimuli in pre- and post-treatment depression. Biol Psychiatry. 2006;60(9):974-986. doi:10.1016/j.biopsych.206.03.024 PubMed (Pubitemid 44584208)
14. Ruhe HG, Booij J, v Weert HC, et al. Evidence why dose-escalation of paroxetine in major depressive disorder is not effective: a 6-week, randomized-controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology. 2009;34:999-1010. PubMed doi:10.1038/np.208.148
15. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P version 2.0). Groenestijn MAC, Akkerhuis GW, Kupka RW, et al, trans-eds [into Dutch]. Lisse, the Netherlands: Swets & Zeitlinger BV; 1999.
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
17. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571. PubMed
18. Saunders K, Simon G, Bush T, et al. Assessing the feasibility of using computerized pharmacy refill data to monitor antidepressant treatment on a population basis: a comparison of automated and self-report data. J Clin Epidemiol. 1998;51(10):883-890. PubMed (Pubitemid 28470131)
19. Ruhe HG, van Rooijen G, Veltman DJ, et al. Six weeks of paroxetine treatment improves dorsolateral prefrontal brain activity. An fMRI study using the Tower of London [abstract]. Eur Neuropsychopharmacol. 2010;20(suppl 3):S380.
20. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage. 2002;15(4):870-878. doi:10.106/nimg.201.1037 PubMed (Pubitemid 34852500)
21. Duvernoy HM. The Human Brain: Surface, Blood Supply, and Three-Dimensional Sectional Anatomy. 2nd ed, revised. Vienna, Austria: Springer; 1999.
22. Liberzon I, Phan KL, Decker LR, et al. Extended amygdala and emotional salience: a PET activation study of positive and negative affect. Neuropsychopharmacology. 2003;28(4):726-733. doi:10.1038/sj.np.13013 PubMed
23. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217-238. doi:10.1038/np.209.10 PubMed
24. Whalen PJ, Rauch SL, Etcoff NL, et al. Masked presentations of emotional facial expressions modulate amygdala activity without explicit knowledge. J Neurosci. 1998;18(1):411-418. PubMed (Pubitemid 28046798)
25. Heimer L, Harlan RE, Alheid GF, et al. Substantia innominata: a notion which impedes clinical-anatomical correlations in neuropsychiatric disorders. Neuroscience. 1997;76(4):957-1006. doi:10.1016/S0306-452(96)0405-8 PubMed (Pubitemid 27016075)
26. Costafreda SG, Brammer MJ, David AS, et al. Predictors of amygdala activation during the processing of emotional stimuli: a meta-analysis of 385 PET and fMRI studies. Brain Res Brain Res Rev. 2008;58(1):57-70. doi:10.1016/j.brainresrev.207.10.012 PubMed
27. Sergerie K, Chochol C, Armony JL. The role of the amygdala in emotional processing: a quantitative meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev. 2008;32(4):811-830. doi:10.1016/j.neubiorev.207.12.02 PubMed
28. Walsh ND, Williams SC, Brammer MJ, et al. A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy. Biol Psychiatry. 2007;62(11):1236-1243. (Pubitemid 350060885)
29. Lane RD, Reiman EM, Ahern GL, et al. Neuroanatomical correlates of happiness, sadness, and disgust. Am J Psychiatry. 1997;154(7):926-933. PubMed (Pubitemid 27274534)
30. Drevets WC. Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci. 1999;877(1):614-637. doi:10.1/j.1749-632.19.tb09292.x PubMed (Pubitemid 29351882)
31. Murphy SE, Norbury R, O'Sullivan U, et al. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry. 2009;194(6):535-540. doi:10.192/bjp.bp.108.056093 PubMed
32. Bigos KL, Pollock BG, Aizenstein HJ, et al. Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology. 2008;33(13):3221-3225. doi:10.1038/np.208.52 PubMed
33. Harmer CJ, Mackay CE, Reid CB, et al. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry. 2006;59(9):816-820. doi:10.1016/j.biopsych.205.10.015 PubMed
34. Norbury R, Mackay CE, Cowen PJ, et al. Short-term antidepressant treatment and facial processing: functional magnetic resonance imaging study. Br J Psychiatry. 2007;190(6):531-532. doi:10.192/bjp.bp.106.031393 PubMed (Pubitemid 46868839)
35. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? a cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009;195(2):102-108. doi:10.192/bjp.bp.108.05193 PubMed
36. Harmer CJ, O'Sullivan U, Favaron E, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009;166(10):1178-1184. doi:10.176/api.ajp.209.09020149 PubMed
37. Dougherty DD, Rauch SL. Brain correlates of antidepressant treatment outcome from neuroimaging studies in depression. Psychiatr Clin North Am. 2007;30(1):91-103. doi:10.1016/j.psc.206.12.07 PubMed (Pubitemid 46386304)
38. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport. 1997;8(4):1057-1061. doi:10.1097/01756-19703030-048 PubMed (Pubitemid 27152174)
39. Chen CH, Suckling J, Ooi C, et al. Functional coupling of the amygdala in depressed patients treated with antidepressant medication. Neuropsychopharmacology. 2008;33(8):1909-1918. doi:10.1038/sj.np.1301593 PubMed (Pubitemid 351832606)
40. Anand A, Li Y, Wang Y, et al. Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study. Neuropsychopharmacology. 2005;30(7):1334-1344. PubMed (Pubitemid 40848087)
41. Pezawas L, Meyer-Lindenberg A, Drabant EM, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci. 2005;8(6):828-834. doi:10.1038/n1463 PubMed (Pubitemid 43085851)
42. Pezawas L, Meyer-Lindenberg A, Goldman AL, et al. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry. 2008;13(7):709-716. doi:10.1038/mp.208.32 PubMed (Pubitemid 351861533)
43. Fisher PM, Meltzer CC, Ziolko SK, et al. Capacity for 5-HT 1A-mediated autoregulation predicts amygdala reactivity. Nat Neurosci. 2006;9(11):1362-1363. doi:10.1038/n1780 PubMed
44. Spindelegger C, Lanzenberger R, Wadsak W, et al. Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders. Mol Psychiatry. 2009;14(11):1040-1050. doi:10.1038/mp.208.35 PubMed
45. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 1994;15(7):220-226. doi:10.1016/0165-6147(94) 90315-8 PubMed (Pubitemid 24210726)
46. Fales CL, Barch DM, Rundle MM, et al. Antidepressant treatment normalizes hypoactivity in dorsolateral prefrontal cortex during emotional interference processing in major depression. J Affect Disord. 2009; 112(1-3):206-211. doi:10.1016/j.jad.208.04.027 PubMed
47. DeRubeis RJ, Siegle GJ, Hollon SD. Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci. 2008;9(10):788-796. doi:10.1038/nrn2345 PubMed
48. Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? a systematic review. Eur Arch Psychiatry Clin Neurosci. 2005;255(6):387-400. doi:10.107/s0406-05-0579-5 PubMed (Pubitemid 43029828)
49. Baker CB, Tweedie R, Duval S, et al. Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. Depress Anxiety. 2003;17(1):1-9. doi:10.102/da.1079 PubMed (Pubitemid 36255237)
50. Ruhe HG, Huyser J, Swinkels JA, et al. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry. 2006;189(4):309-316. doi:10.192/bjp.bp.105.018325 PubMed (Pubitemid 44606743)
51. Chen CH, Ridler K, Suckling J, et al. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry. 2007;62(5):407-414. doi:10.1016/j.biopsych.206.09.018 PubMed (Pubitemid 47284016)
52. Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry. 2000;48(8):830-843.